Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-23-013470)

Filing Details

Accession Number:: 0001209191-23-013470
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-27 21:00:34
Reporting Period:: 2023-02-23

Accepted Time:: 2023-02-27 21:00:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1899977	C. Mark Schneyer	C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130	Evp, Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-02-23	1,353	$0.00	4,695	No	4	M	Direct
Common Stock	Disposition	2023-02-24	577	$18.78	4,118	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-02-23	1,353	$0.00	1,353	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,706			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
The restricted stock units vest in four equal annual installments beginning February 23, 2022.